Cranioplasty, vertebral body replacement, and spinal fusion with tobramycin-impregnated methylmethacrylate

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A prospective analysis of cranioplasty, vertebral body replacement, and spinal fusion using tobramycin-impregnated methylmethacrylate in 65 patients is presented. Cranioplastic methacrylate (1 packet) was mixed with 1.2 g of powdered tobramycin and placed into the desired location. The polymer was irrigated with bacitracin until it became solid. All patients received prophylactic medication with intravenously administered nafcillin and cephalosporin perioperatively and for 48 hours postoperatively. The follow-up time ranged from 7 to 57 months (mean, 32.2 months). Serum tobramycin levels remained below 0.5 μg/ml in all patients tested, regardless of the time interval. Blood urea nitrogen and creatinine levels remained within normal limits in all patients, and there has been no nephrotoxicity or ototoxicity. There has been 1 infection among the 65 patients (1%) to date. It occurred in a patient who had a previously treated local infection. Cranioplasty, vertebral body replacement, or spinal fusion with tobramycin-impregnated methylmethacrylate is safe and may reduce the incidence of infection.

Original languageEnglish (US)
Pages (from-to)789-791
Number of pages3
JournalNeurosurgery
Volume28
Issue number6
StatePublished - 1991

Fingerprint

Methylmethacrylate
Spinal Fusion
Tobramycin
Nafcillin
Infection
Bacitracin
Methacrylates
Blood Urea Nitrogen
Cephalosporins
Creatinine
Polymers
Incidence
Serum

Keywords

  • Cranioplasty
  • Infection
  • Methacrylate
  • Tobramycin

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Cranioplasty, vertebral body replacement, and spinal fusion with tobramycin-impregnated methylmethacrylate. / Shapiro, Scott.

In: Neurosurgery, Vol. 28, No. 6, 1991, p. 789-791.

Research output: Contribution to journalArticle

@article{b64a0bb6b7af4169aa8283564d69ba71,
title = "Cranioplasty, vertebral body replacement, and spinal fusion with tobramycin-impregnated methylmethacrylate",
abstract = "A prospective analysis of cranioplasty, vertebral body replacement, and spinal fusion using tobramycin-impregnated methylmethacrylate in 65 patients is presented. Cranioplastic methacrylate (1 packet) was mixed with 1.2 g of powdered tobramycin and placed into the desired location. The polymer was irrigated with bacitracin until it became solid. All patients received prophylactic medication with intravenously administered nafcillin and cephalosporin perioperatively and for 48 hours postoperatively. The follow-up time ranged from 7 to 57 months (mean, 32.2 months). Serum tobramycin levels remained below 0.5 μg/ml in all patients tested, regardless of the time interval. Blood urea nitrogen and creatinine levels remained within normal limits in all patients, and there has been no nephrotoxicity or ototoxicity. There has been 1 infection among the 65 patients (1{\%}) to date. It occurred in a patient who had a previously treated local infection. Cranioplasty, vertebral body replacement, or spinal fusion with tobramycin-impregnated methylmethacrylate is safe and may reduce the incidence of infection.",
keywords = "Cranioplasty, Infection, Methacrylate, Tobramycin",
author = "Scott Shapiro",
year = "1991",
language = "English (US)",
volume = "28",
pages = "789--791",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cranioplasty, vertebral body replacement, and spinal fusion with tobramycin-impregnated methylmethacrylate

AU - Shapiro, Scott

PY - 1991

Y1 - 1991

N2 - A prospective analysis of cranioplasty, vertebral body replacement, and spinal fusion using tobramycin-impregnated methylmethacrylate in 65 patients is presented. Cranioplastic methacrylate (1 packet) was mixed with 1.2 g of powdered tobramycin and placed into the desired location. The polymer was irrigated with bacitracin until it became solid. All patients received prophylactic medication with intravenously administered nafcillin and cephalosporin perioperatively and for 48 hours postoperatively. The follow-up time ranged from 7 to 57 months (mean, 32.2 months). Serum tobramycin levels remained below 0.5 μg/ml in all patients tested, regardless of the time interval. Blood urea nitrogen and creatinine levels remained within normal limits in all patients, and there has been no nephrotoxicity or ototoxicity. There has been 1 infection among the 65 patients (1%) to date. It occurred in a patient who had a previously treated local infection. Cranioplasty, vertebral body replacement, or spinal fusion with tobramycin-impregnated methylmethacrylate is safe and may reduce the incidence of infection.

AB - A prospective analysis of cranioplasty, vertebral body replacement, and spinal fusion using tobramycin-impregnated methylmethacrylate in 65 patients is presented. Cranioplastic methacrylate (1 packet) was mixed with 1.2 g of powdered tobramycin and placed into the desired location. The polymer was irrigated with bacitracin until it became solid. All patients received prophylactic medication with intravenously administered nafcillin and cephalosporin perioperatively and for 48 hours postoperatively. The follow-up time ranged from 7 to 57 months (mean, 32.2 months). Serum tobramycin levels remained below 0.5 μg/ml in all patients tested, regardless of the time interval. Blood urea nitrogen and creatinine levels remained within normal limits in all patients, and there has been no nephrotoxicity or ototoxicity. There has been 1 infection among the 65 patients (1%) to date. It occurred in a patient who had a previously treated local infection. Cranioplasty, vertebral body replacement, or spinal fusion with tobramycin-impregnated methylmethacrylate is safe and may reduce the incidence of infection.

KW - Cranioplasty

KW - Infection

KW - Methacrylate

KW - Tobramycin

UR - http://www.scopus.com/inward/record.url?scp=0025907251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025907251&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 789

EP - 791

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 6

ER -